Find a Doctor |
New Search | Return to Search Results |
Cancer Surgery, endocrine surgery and cancer research (tumor angiogenesis, antiangiogenic gene therapy, regional perfusion therapy of malignant lesions, and isolation and characterization of unique tumor cytokines).
Dr. Libutti’s clinical practice is focused on the surgical management of patients with cancer and endocrine neoplasms. Dr. Libutti’s research, which began at the National Cancer Institute (NCI), focuses on the formation of new blood vessels, which nourish tumors, as well as the interaction between tumor cells, endothelial cells, and components of the tumor microenvironment that influence tumor growth, invasion and spread. He and his team utilize a variety of in vitro and in vivo model systems, as well as noninvasive imaging techniques, including MRI and PET, to map changes in tumor blood flow within tumors in order to study tumor cell and endothelial cell interactions. By better understanding the relationship between tumors and their blood supply, he and his research team have developed groundbreaking therapies for patients with cancer. Dr. Libutti was the first to administer TNF bound colloidal gold nanoparticles as targeted therapy to cancer patients, and he continues to discover novel treatment solutions through his ongoing clinical and research efforts.
Biography: Steven K. Libutti, MD, is one of the pioneers of regional and targeted cancer therapy as well as an internationally recognized surgical oncologist and endocrine surgeon. After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured senior investigator and chief of the Tumor Angiogenesis Section. His clinical expertise is in the management of malignancies of the liver, pancreas, and GI tract, and in applying laparoscopic surgery to managing patients with malignancies. He also provides surgical consultation and treatment for patients with disorders of the thyroid, parathyroid, and adrenal glands.
|
||||||||||||||||||||||||||||||||
| Medical Education: |
M.D., Columbia Univ College of Physicians and Surgeons |
| Residency: |
New York Presbyterian Hospital |
| Fellowship: |
National Institutes of Health |
| Board Certified: |
Surgery |
Publications:
Here is a list of selected publications for Dr. Libutti:
Shen HC, He M, Powell A, Adem A, Lorang D, Heller C, Grover AC, Ylaya K, Hewitt SM, Marx SJ, Spiegel AM, Libutti SK. Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res. 2009 Mar 1;69(5):1858-66. Epub 2009 Feb 10. PMID: 19208834 [PubMed - in process]
Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A,Starker E, Hewitt S, Libutti SK. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer. 2009 Jan 1;115(1):128-39. PMID: 19090007 [PubMed - in process]
Hanna E, Quick J, Libutti SK. The tumour microenvironment: a novel target for cancer therapy. Oral Dis. 2009 Jan;15(1):8-17. Epub 2008 Nov 1. PMID: 18992016 [PubMed - in process]
Powell AC, Alexander HR, Pingpank JF, Steinberg SM, Skarulis M, Bartlett DL, Agarwal S, Cochran C, Seidel G, Fraker D, Hughes MS, Jensen RT, Marx SJ, Libutti SK. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery. 2008 Dec;144(6):878-83; discussion 883-4. PMID: 19040992 [PubMed - indexed for MEDLINE]
Kwon M, Hanna E, Lorang D, He M, Quick JS, Adem A,Stevenson C, Chung JY, Hewitt SM, Zudaire E, Esposito D, Cuttitta F, Libutti SK. Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy.Cancer Res. 2008 Sep 15;68(18):7332-41. PMID: 18794120 [PubMed - indexed for MEDLINE]
Powell AC, Stratakis CA, Patronas NJ, Steinberg SM, Batista D, Alexander HR,Pingpank JF, Keil M, Bartlett DL, Libutti SK. Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia. Surgery. 2008 Jun;143(6):750-8. PMID: 18549891 [PubMed - indexed for MEDLINE]
Shen HC, Rosen JE, Yang LM, Savage SA, Burns AL, Mateo CM, Agarwal SK,Chandrasekharappa SC, Spiegel AM, Collins FS, Marx SJ, Libutti SK. Parathyroid tumor development involves deregulation of homeobox genes. Endocr Relat Cancer. 2008 Mar;15(1):267-75. PMID: 18310293 [PubMed - indexed for MEDLINE]
Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res. 2008 Jan 1;14(1):270-80. PMID: 18172279 [PubMed - indexed for MEDLINE]
Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR,Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, Linehan WM, Libutti SK. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms(PNETs). Surgery. 2007 Dec;142(6):814-8; discussion 818.e1-2. Erratum in: Surgery. 2008 Feb;143(2):302. PMID: 18063061 [PubMed - indexed for MEDLINE]
View more of Dr. Libutti's publications on Pubmed
You have not yet added any physicians to your list
Your physician list will
only be saved for as long
as your current visit to
this site.